Last 7 days
-1.6%
Last 30 days
-7.2%
Last 90 days
-7.3%
Trailing 12 Months
37.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 124.2B | 26.3B | -2.34% | 1.62% | 18.96 | 4.72 | 1.32% | 11.18% |
GILD | 98.0B | 27.3B | -7.18% | 37.83% | 21.33 | 3.59 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | -7.28% | -16.95% | 6.83 | 2.97 | 4.29% | -31.47% |
BIIB | 38.1B | 10.2B | -3.01% | 25.82% | 12.5 | 3.74 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.2B | 1.5B | -6.54% | 2.94% | 59.61 | 6.19 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -20.63% | -31.77% | -9.51 | 28.59 | 122.90% | -12.19% |
BEAM | 2.2B | 60.9M | -22.54% | -46.32% | -7.52 | 35.66 | 17.51% | 22.00% |
BBIO | 1.9B | 107.9M | 7.80% | 19.42% | -3.99 | 17.93 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -12.49% | -50.70% | -4.44 | 10.58 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -19.12% | 19.58% | -7.01 | 156.87 | 131.81% | -45.39% |
FATE | 507.9M | 96.3M | -13.43% | -85.87% | -1.8 | 5.27 | 72.44% | -32.79% |
NVAX | 499.9M | 2.0B | -38.13% | -92.75% | -0.76 | 0.25 | 72.89% | 62.27% |
SGMO | 278.5M | 111.3M | -41.20% | -71.01% | -1.45 | 2.5 | 0.54% | -7.86% |
VXRT | 98.0M | 107.0K | -22.42% | -85.54% | -0.91 | 915.57 | -88.00% | -52.91% |
IBIO | 26.6M | - | 29.52% | -80.89% | -0.33 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.5% | 27,281 | 27,136 | 27,515 | 27,472 | 27,305 |
S&GA Expenses | 7.0% | 5,673 | 5,303 | 5,280 | 5,274 | 5,246 |
Costs and Expenses | -5.6% | 19,951 | 21,133 | 20,507 | 20,247 | 17,387 |
EBITDA | 21.5% | 7,072 | 5,819 | 6,848 | 7,175 | - |
EBITDA Margin | 20.9% | 0.26* | 0.21* | 0.25* | 0.26* | - |
Earnings Before Taxes | 28.0% | 5,814 | 4,542 | 5,548 | 5,862 | 8,278 |
EBT Margin | 27.3% | 0.21* | 0.17* | 0.20* | 0.21* | - |
Interest Expenses | -1.3% | 935 | 947 | 968 | 982 | 1,001 |
Net Income | 37.7% | 4,592 | 3,334 | 4,137 | 4,515 | 6,225 |
Net Income Margin | 37.0% | 0.17* | 0.12* | 0.15* | 0.16* | - |
Free Cahsflow | -7.4% | 8,344 | 9,007 | 9,415 | 9,953 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.0% | 63,171 | 62,557 | 62,870 | 63,080 | 67,952 |
Current Assets | 6.6% | 14,443 | 13,554 | 13,175 | 12,629 | 14,772 |
Cash Equivalents | 15.2% | 5,412 | 4,699 | 4,739 | 4,296 | 5,338 |
Inventory | 3.0% | 1,507 | 1,463 | 1,494 | 1,482 | 1,618 |
Net PPE | 2.4% | 5,475 | 5,349 | 5,299 | 5,253 | 5,121 |
Goodwill | 0% | 8,314 | 8,314 | 8,314 | 8,314 | 8,332 |
Current Liabilities | 7.8% | 11,237 | 10,423 | 9,220 | 8,558 | 11,610 |
Long Term Debt | -3.8% | 25,223 | 26,216 | 26,208 | 26,695 | - |
LT Debt, Current | 122.3% | 2,270 | 1,021 | 1,025 | 1,516 | - |
LT Debt, Non Current | 0.0% | 22,957 | 22,953 | 25,195 | 25,183 | 25,179 |
Shareholder's Equity | 0.8% | 21,240 | 21,081 | 20,215 | 19,915 | 21,069 |
Retained Earnings | -0.4% | 15,687 | 15,756 | 15,117 | 14,986 | 16,324 |
Additional Paid-In Capital | 6.2% | 5,550 | 5,226 | 5,031 | 4,867 | 4,661 |
Accumulated Depreciation | - | 1,893 | - | - | - | - |
Shares Outstanding | -0.6% | 1,247 | 1,254 | 1,254 | 1,255 | 1,254 |
Minority Interest | -29.2% | -31.00 | -24.00 | -21.00 | -12.00 | -5.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -6.6% | 9,072 | 9,710 | 10,100 | 10,614 | 11,384 |
Share Based Compensation | 2.4% | 637 | 622 | 625 | 626 | 635 |
Cashflow From Investing | -4.1% | -2,466 | -2,369 | -1,890 | -2,159 | -3,131 |
Cashflow From Financing | 5.7% | -6,469 | -6,857 | -8,266 | -8,194 | -8,877 |
Dividend Payments | 0.6% | 3,709 | 3,688 | 3,659 | 3,633 | 3,605 |
Buy Backs | 95.8% | 1,396 | 713 | 668 | 633 | 546 |
51.9%
0%
0%
Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.
8.5%
1.3%
5.4%
6.7%
FIve years rolling returns for Gilead Sciences.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 23.48 | 1,068,530 | 2,560,530 | 0.07% |
2023-03-13 | Claro Advisors LLC | reduced | -13.93 | 73,231 | 445,231 | 0.15% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -5.9 | 47,911,600 | 202,688,000 | 0.22% |
2023-03-10 | MATHER GROUP, LLC. | added | 1.48 | 225,887 | 772,887 | 0.01% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -3.95 | 517,194 | 2,052,190 | 0.32% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -14.87 | 113,665 | 621,665 | 0.05% |
2023-03-06 | OLD MISSION CAPITAL LLC | sold off | -100 | -448,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -35.6 | -1,266,000 | 10,922,000 | 0.06% |
2023-03-03 | TIAA, FSB | reduced | -76.76 | -8,940,820 | 4,273,180 | 0.02% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 1,427,510 | 1,427,510 | 0.02% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital research global investors | 4.4% | 54,602,952 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 5.5% | 68,900,998 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.93% | 112,038,324 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 10.5% | 131,555,769 | SC 13G/A | |
Jul 08, 2022 | blackrock inc. | 10.1% | 126,932,693 | SC 13G | |
Feb 11, 2022 | capital research global investors | 8.5% | 107,156,981 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.43% | 105,803,799 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 9.5% | 118,961,206 | SC 13G/A | |
Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A | |
Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 21.64 -72.45% | 27.25 -65.31% | 43.63 -44.46% | 72.06 -8.27% | 87.89 11.88% |
Current Inflation | 20.58 -73.80% | 25.77 -67.20% | 40.40 -48.57% | 63.07 -19.72% | 76.28 -2.90% |
Very High Inflation | 19.20 -75.56% | 23.86 -69.63% | 36.36 -53.72% | 52.66 -32.97% | 62.94 -19.88% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 3 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-13 | Parsey Merdad | sold | -483,893 | 78.99 | -6,126 | chief medical officer |
2023-03-10 | O'Day Daniel Patrick | acquired | - | - | 30,288 | chairman & ceo |
2023-03-10 | Parsey Merdad | sold (taxes) | -423,576 | 79.5 | -5,328 | chief medical officer |
2023-03-10 | Patterson Sandra | sold (taxes) | -63,679 | 79.5 | -801 | svp, controllership |
2023-03-10 | Patterson Sandra | acquired | - | - | 2,921 | svp, controllership |
2023-03-10 | Parsey Merdad | acquired | - | - | 11,454 | chief medical officer |
2023-03-10 | O'Day Daniel Patrick | sold (taxes) | -1,114,350 | 79.5 | -14,017 | chairman & ceo |
2023-03-10 | Dickinson Andrew D | sold (taxes) | -385,496 | 79.5 | -4,849 | chief financial officer |
2023-03-10 | Mercier Johanna | acquired | - | - | 10,976 | chief commercial officer |
2023-03-10 | Mercier Johanna | sold (taxes) | -406,722 | 79.5 | -5,116 | chief commercial officer |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Total revenues | $ 27,281 | $ 27,305 | $ 24,689 |
Costs and expenses: | |||
Cost of goods sold | 5,657 | 6,601 | 4,572 |
Research and development expenses | 4,977 | 4,601 | 4,927 |
Acquired in-process research and development expenses | 944 | 939 | 5,968 |
In-process research and development impairment | 2,700 | 0 | 0 |
Selling, general and administrative expenses | 5,673 | 5,246 | 5,151 |
Total costs and expenses | 19,951 | 17,387 | 20,618 |
Operating income | 7,330 | 9,918 | 4,071 |
Interest expense | (935) | (1,001) | (984) |
Other income (expense), net | (581) | (639) | (1,418) |
Income before income taxes | 5,814 | 8,278 | 1,669 |
Income tax expense | (1,248) | (2,077) | (1,580) |
Net income | 4,566 | 6,201 | 89 |
Net loss attributable to noncontrolling interest | 26 | 24 | 34 |
Net income attributable to Gilead | $ 4,592 | $ 6,225 | $ 123 |
Basic earnings per share attributable to Gilead (in dollars per share) | $ 3.66 | $ 4.96 | $ 0.10 |
Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,255 | 1,256 | 1,257 |
Diluted earnings per share attributable to Gilead (in dollars per share) | $ 3.64 | $ 4.93 | $ 0.10 |
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,262 | 1,262 | 1,263 |
Product sales | |||
Revenues: | |||
Total revenues | $ 26,982 | $ 27,008 | $ 24,355 |
Royalty, contract and other revenues | |||
Revenues: | |||
Total revenues | $ 299 | $ 297 | $ 334 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,412 | $ 5,338 |
Short-term marketable debt securities | 973 | 1,182 |
Accounts receivable, net | 4,777 | 4,493 |
Inventories | 1,507 | 1,618 |
Prepaid and other current assets | 1,774 | 2,141 |
Total current assets | 14,443 | 14,772 |
Property, plant and equipment, net | 5,475 | 5,121 |
Long-term marketable debt securities | 1,245 | 1,309 |
Intangible assets, net | 28,894 | 33,455 |
Goodwill | 8,314 | 8,332 |
Other long-term assets | 4,800 | 4,963 |
Total assets | 63,171 | 67,952 |
Current liabilities: | ||
Accounts payable | 905 | 705 |
Accrued rebates | 3,479 | 3,244 |
Other current liabilities | 4,580 | 6,145 |
Current portion of long-term debt and other obligations, net | 2,273 | 1,516 |
Total current liabilities | 11,237 | 11,610 |
Long-term debt, net | 22,957 | 25,179 |
Long-term income taxes payable | 3,916 | 4,767 |
Deferred tax liability | 2,673 | 4,356 |
Other long-term obligations | 1,179 | 976 |
Commitments and contingencies (Note 13) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively | 1 | 1 |
Additional paid-in capital | 5,550 | 4,661 |
Accumulated other comprehensive income | 2 | 83 |
Retained earnings | 15,687 | 16,324 |
Total Gilead stockholders’ equity | 21,240 | 21,069 |
Noncontrolling interest | (31) | (5) |
Total stockholders’ equity | 21,209 | 21,064 |
Total liabilities and stockholders’ equity | $ 63,171 | $ 67,952 |